Lalani HS - Search Results

1

Potential Medicare Part D Savings on Generic Drugs From the Mark Cuban Cost Plus Drug Company.

Lalani HS, Kesselheim AS, Rome BN. Lalani HS, et al. Ann Intern Med. 2022 Jul;175(7):1053-1055. doi: 10.7326/M22-0756. Epub 2022 Jun 21. Ann Intern Med. 2022. PMID: 35724381 No abstract available.

2

US Taxpayers Heavily Funded the Discovery of COVID-19 Vaccines.

Lalani HS, Avorn J, Kesselheim AS. Lalani HS, et al. Clin Pharmacol Ther. 2022 Mar;111(3):542-544. doi: 10.1002/cpt.2344. Epub 2021 Jul 9. Clin Pharmacol Ther. 2022. PMID: 34243221 Free PMC article. No abstract available.

3

Direct-to-Consumer Generic Drugs: A Maverick Approach or Another Exposure of Market Failures?

Lalani HS, Kesselheim AS, Rome BN. Lalani HS, et al. Ann Intern Med. 2022 Jun;175(6):890-891. doi: 10.7326/M22-0740. Epub 2022 Apr 19. Ann Intern Med. 2022. PMID: 35436150 No abstract available.

4

Get Out the Vote: A Framework to Mobilize Medical Professionals to Vote.

Lalani HS, Hong AS. Lalani HS, et al. Ann Intern Med. 2022 Oct;175(10):1476-1478. doi: 10.7326/M22-2168. Epub 2022 Sep 13. Ann Intern Med. 2022. PMID: 36095309 No abstract available.

5

US public investment in development of mRNA covid-19 vaccines: retrospective cohort study.

Lalani HS, Nagar S, Sarpatwari A, Barenie RE, Avorn J, Rome BN, Kesselheim AS. Lalani HS, et al. BMJ. 2023 Mar 1;380:e073747. doi: 10.1136/bmj-2022-073747. BMJ. 2023. PMID: 36858453 Free PMC article.

6

The Credibility Conundrum: Can Social Media Companies Define Credibility for Users?

Lalani HS, Laine C. Lalani HS, et al. Ann Intern Med. 2023 May;176(5):721-722. doi: 10.7326/M23-0490. Epub 2023 Mar 7. Ann Intern Med. 2023. PMID: 36877967 No abstract available.

7

Addressing Viral Medical Rumors and False or Misleading Information.

Lalani HS, DiResta R, Baron RJ, Scales D. Lalani HS, et al. Ann Intern Med. 2023 Aug;176(8):1113-1120. doi: 10.7326/M23-1218. Epub 2023 Jul 18. Ann Intern Med. 2023. PMID: 37459614 Free article. Review.

8

Identifying therapeutic alternatives in Medicare drug price negotiation: The case of etanercept.

Mooney H, Martin M, Bendicksen L, Kesselheim AS, Rome BN, Lalani HS. Mooney H, et al. Among authors: lalani hs. J Manag Care Spec Pharm. 2024 Mar 1;30(3):226-233. doi: 10.18553/jmcp.2023.23209. Epub 2023 Dec 13. J Manag Care Spec Pharm. 2024. PMID: 38088900

9

Administrative action on drug pricing: Lessons and opportunities for the Center for Medicare and Medicaid Innovation.

Liu ITT, Lalani HS, Kesselheim AS. Liu ITT, et al. Among authors: lalani hs. J Manag Care Spec Pharm. 2024 Mar 1;30(3):290-301. doi: 10.18553/jmcp.2023.23208. Epub 2023 Dec 23. J Manag Care Spec Pharm. 2024. PMID: 38140903

10

Association between changes in prices and out-of-pocket costs for brand-name clinician-administered drugs.

Lalani HS, Russo M, Desai RJ, Kesselheim AS, Rome BN. Lalani HS, et al. Health Serv Res. 2024 Jan 21. doi: 10.1111/1475-6773.14279. Online ahead of print. Health Serv Res. 2024. PMID: 38247110

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

25 results

Search Page